Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). Identifying effective small-molecular drugs in the early phases of drug discovery is now one of the biggest business challenges in the pharmaceutical industry. In the conventional approach to discovering drugs, the process of identifying the active substance often starts with the use of high pass screening methods (HTS) alongside rational design. Unfortunately, this approach has considerable limitations: it is time-consuming, costly, requires automated equipment, significant amounts of protein are required to perform biophysical, biochemical or cell tests. DNA encoded libraries can be a solution to these inconveniences. They are collections of small molecular organic compounds marked with short oligonulotide, which serves as a recognition code for identifying the attached substance. The testing process (selection) is based on affinity method and is universal for many proteins. DEL technology has significant benefits compared to HTS: multimillion-million-dollar collections of compounds are stored in small samples, and screening takes place using micromole amounts of protein target in a short period of time at preferential prices. The direct result of the project will be an innovative library of 1 million DNA-coded compounds, which will serve as a modern tool for identifying active substances for selected protein targets relevant in civilisation diseases such as cancer. Implementation will include identification of novel hits with secure intellectual rights for Selvita, resynthesis of hits without DNA codes, validation of substances using biophysical, biochemical methods